Latest Insider Transactions at Avantor, Inc. (AVTR)
This section provides a real-time view of insider transactions for Avantor, Inc. (AVTR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Avantor, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Avantor, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 23
2022
|
Justin Miller EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+6.83%
|
-
|
|
Feb 23
2022
|
Sheri Lewis EVP, Global Ops & Supply Chain |
BUY
Grant, award, or other acquisition
|
Direct |
9,822
+11.92%
|
-
|
|
Feb 23
2022
|
Meghan Henson EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,311
+20.45%
|
-
|
|
Feb 23
2022
|
Steven W Eck SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,138
+21.43%
|
-
|
|
Feb 23
2022
|
Christophe Couturier EVP, AMEA |
BUY
Grant, award, or other acquisition
|
Direct |
6,044
+4.97%
|
-
|
|
Feb 23
2022
|
Gerard Brophy EVP, Biopharma Production |
BUY
Grant, award, or other acquisition
|
Direct |
15,110
+9.72%
|
-
|
|
Feb 23
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
3,059
-2.39%
|
$100,947
$33.79 P/Share
|
|
Feb 23
2022
|
Thomas A Szlosek EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
16,621
+6.12%
|
-
|
|
Feb 23
2022
|
Frederic Vanderhaegen EVP, Americas and Europe |
BUY
Grant, award, or other acquisition
|
Direct |
15,110
+8.24%
|
-
|
|
Feb 20
2022
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
448
-3.17%
|
$15,232
$34.0 P/Share
|
|
Feb 20
2022
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
398
-0.26%
|
$11,144
$28.69 P/Share
|
|
Feb 20
2022
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,959
-0.87%
|
$372,606
$34.0 P/Share
|
|
Feb 20
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
3,072
-2.34%
|
$104,448
$34.0 P/Share
|
|
Feb 20
2022
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,267
-1.14%
|
$43,078
$34.0 P/Share
|
|
Feb 20
2022
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,040
-1.67%
|
$137,360
$34.0 P/Share
|
|
Feb 20
2022
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,328
-1.52%
|
$45,152
$34.0 P/Share
|
|
Jan 13
2022
|
Mark Christopher Murray EVP, Biomaterials & AT |
SELL
Payment of exercise price or tax liability
|
Direct |
918
-4.68%
|
$33,966
$37.5 P/Share
|
|
Jan 05
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
11,551
-8.09%
|
$438,938
$38.65 P/Share
|
|
Jan 03
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
59,418
-29.37%
|
$2,376,720
$40.77 P/Share
|
|
Jan 03
2022
|
Gerard Brophy EVP, Biopharma Production |
BUY
Exercise of conversion of derivative security
|
Direct |
59,418
+22.7%
|
$1,069,524
$18.45 P/Share
|
|
Jan 02
2022
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
1,017
-0.66%
|
$42,714
$42.14 P/Share
|
|
Jan 02
2022
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,101
-3.24%
|
$340,242
$42.14 P/Share
|
|
Jan 02
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
6,516
-4.36%
|
$273,672
$42.14 P/Share
|
|
Jan 02
2022
|
Michael Wondrasch EVP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,517
-8.36%
|
$399,714
$42.14 P/Share
|
|
Dec 31
2021
|
Sheri Lewis EVP, Global Ops & Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
4,093
-6.12%
|
$171,906
$42.14 P/Share
|
|
Dec 31
2021
|
Meghan Henson EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,877
-7.25%
|
$78,834
$42.14 P/Share
|
|
Dec 27
2021
|
Christophe Couturier EVP, AMEA |
SELL
Open market or private sale
|
Direct |
10,184
-8.44%
|
$417,544
$41.63 P/Share
|
|
Dec 27
2021
|
Christophe Couturier EVP, AMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
10,184
+7.78%
|
$234,232
$23.21 P/Share
|
|
Dec 22
2021
|
Christophe Couturier EVP, AMEA |
SELL
Open market or private sale
|
Direct |
28,125
-20.29%
|
$1,153,125
$41.53 P/Share
|
|
Dec 22
2021
|
Christophe Couturier EVP, AMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
28,125
+16.87%
|
$646,875
$23.21 P/Share
|
|
Dec 21
2021
|
Christophe Couturier EVP, AMEA |
SELL
Open market or private sale
|
Direct |
38,309
-25.74%
|
$1,570,669
$41.0 P/Share
|
|
Dec 21
2021
|
Christophe Couturier EVP, AMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
38,309
+20.47%
|
$881,107
$23.21 P/Share
|
|
Dec 09
2021
|
Christophe Couturier EVP, AMEA |
SELL
Open market or private sale
|
Direct |
7,859
-6.64%
|
$314,360
$40.24 P/Share
|
|
Dec 09
2021
|
Christophe Couturier EVP, AMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
7,859
+6.23%
|
$133,603
$17.67 P/Share
|
|
Dec 08
2021
|
Christophe Couturier EVP, AMEA |
SELL
Open market or private sale
|
Direct |
5,828
-5.01%
|
$233,120
$40.0 P/Share
|
|
Dec 08
2021
|
Christophe Couturier EVP, AMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
5,828
+4.77%
|
$99,076
$17.67 P/Share
|
|
Dec 01
2021
|
Rajiv Gupta Director |
SELL
Open market or private sale
|
Direct |
100,000
-10.21%
|
$3,900,000
$39.3 P/Share
|
|
Nov 12
2021
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Open market or private sale
|
Direct |
80,000
-34.12%
|
$3,040,000
$38.25 P/Share
|
|
Nov 12
2021
|
Frederic Vanderhaegen EVP, Americas and Europe |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+25.44%
|
$1,840,000
$23.2 P/Share
|
|
Nov 11
2021
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Open market or private sale
|
Direct |
60,804
-28.24%
|
$2,310,552
$38.41 P/Share
|
|
Nov 08
2021
|
Joseph R Massaro Director |
BUY
Grant, award, or other acquisition
|
Direct |
745
+50.0%
|
-
|
|
Nov 01
2021
|
Rajiv Gupta Director |
SELL
Open market or private sale
|
Direct |
100,000
-9.26%
|
$4,000,000
$40.31 P/Share
|
|
Oct 28
2021
|
Mala Murthy Director |
BUY
Grant, award, or other acquisition
|
Direct |
916
+50.0%
|
-
|
|
Oct 01
2021
|
Rajiv Gupta Director |
SELL
Open market or private sale
|
Direct |
100,000
-8.48%
|
$3,900,000
$39.94 P/Share
|
|
Sep 20
2021
|
Michael Stubblefield President & CEO |
SELL
Open market or private sale
|
Direct |
141,300
-10.07%
|
$5,934,600
$42.37 P/Share
|
|
Sep 01
2021
|
Rajiv Gupta Director |
SELL
Open market or private sale
|
Direct |
100,000
-7.82%
|
$3,900,000
$39.45 P/Share
|
|
Aug 26
2021
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
17,383
-55.13%
|
$695,320
$40.08 P/Share
|
|
Aug 20
2021
|
Rajiv Gupta Director |
SELL
Open market or private sale
|
Direct |
100,000
-7.25%
|
$3,800,000
$38.81 P/Share
|
|
Jul 30
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
81,125
-35.19%
|
$3,001,625
$37.24 P/Share
|
|
Jul 30
2021
|
Gerard Brophy EVP, Biopharma Production |
BUY
Exercise of conversion of derivative security
|
Direct |
81,125
+26.03%
|
$1,865,875
$23.2 P/Share
|